Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of V221 Given Concomitantly With Pneumococcal Conjugate Vaccine in Healthy Children 12 to 15 Months of Age

Next Previous
X
Search
Trial Profile

An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of V221 Given Concomitantly With Pneumococcal Conjugate Vaccine in Healthy Children 12 to 15 Months of Age

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MMR-varicella zoster virus vaccine (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Chickenpox; Measles; Mumps; Pneumococcal infections; Rubella
  • Focus Pharmacodynamics; Registrational
  • Sponsors Merck Sharp & Dohme

    • Most Recent Events

    • 16 Feb 2010 Primary endpoints identified as reported by ClinicalTrials.gov.
    • 19 Feb 2009 Planned number of patients changed from 600 to 1027 as reported by ClinicalTrials.gov.
    • 03 Aug 2008 Additional trial identifier V221-019 reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top